Navigation Links
Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results
Date:2/14/2008

ic nephropathy and we are

actively pursuing ways to monetize this asset.

-- Extended our research collaboration agreement with Bristol-Myers

Squibb Company to develop and commercialize novel therapies targeted

against the Liver X Receptor. We also received a milestone payment of

$5.0 million from Bristol-Myers Squibb as a result of the acceptance

of an IND, or foreign equivalent.

-- Submitted XL139 to Bristol-Myers Squibb Company in December 2007 under

our oncology collaboration agreement. In January 2008, Bristol-Myers

Squibb exercised its option to develop and commercialize XL139,

thereby triggering a $20.0 million selection milestone payment, and we

exercised our option to co-develop and co-commercialize the compound

in the United States and receive royalties on product sales outside of

the United States.

-- Received $18.0 million from the sale of a major portion of our plant

trait assets to Agrigenetics, Inc., a wholly-owned subsidiary of The

Dow Chemical Company.

-- Sold an 80.1% stake in Artemis to Taconic Farms, for $19.8 million.

Corporate Development

-- Completed a public offering of common stock, raising net proceeds of

$71.9 million.

-- Appointed Richard E. Buller, M.D., Ph.D. to the newly created position

of Vice President, Translational Medicine, Arthur DeCillis, M.D. to

the position of Vice President, Clinical Research, and Anne Champsaur,

M.D. to the position of Vice President, Drug Safety.

-- Appointed Jose Baselga, M.D., a leading expert in oncology drug

discovery, to our Scientific Advisory Board.

-- Appointed Carl B. Feldbaum, president emeritus of the Biotechnology

Industry Organization, to our Board of Directors.

"2007 was an exceptional year in the growth and development of Exelixis -- w
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
4. Exelixis Announces Senior Management Promotions
5. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
6. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
7. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
8. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
11. Exelixis Sells 80% Stake in Artemis to Taconic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... YONGIN, South Korea , June 1, ... Green Cross Biotherapeutics Inc. (GCBT) kicked off construction today ... the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 million project ... in Canada in the biopharmaceutical ... intravenous immunoglobulin (IVIG) and albumin manufacturing plant in ...
(Date:6/1/2015)... , June 1, 2015 ... Decipher® genomic analysis platform, successfully classified various ... genomic expression of certain biomarkers, including one ... Importantly, this unique genomic signature has potential ... to neoadjuvant chemotherapy in patients with muscle-invasive ...
(Date:6/1/2015)... 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... 2015.  Biorem,s complete 2015 first quarter financial statements and MD&A have ... ended March 31,(in CDN$,000 except per share data) , ... , 1,974 Gross profit , 1,531 , ... (loss) , 528 , (531) Basic earnings (loss) ...
(Date:6/1/2015)... , June 1, 2015 ... announced the addition of the "Global PDT ... offering.        (Logo: ... Report 2014 is a professional and in-depth study ... , ,The report provides a basic overview of ...
Breaking Biology Technology:Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Global PDT Machine Industry Report 2014 2
... Chinmax Medical Systems Inc., a leading cardiac biomarker distributor ... its lawsuit against Inverness Medical Beijing (IMB), a subsidiary ... the Complaint, Inverness Medical Beijing secretly imported massive quantities ... customers during the period when Chinmax retained the undisputed ...
... April 11, 2011 Leading experts from around the world ... the 6th Canine Vector Borne Disease (CVBD) forum in Nice, ... to animals and humans by these increasingly important diseases. ... and even death in dogs, and many CVBDs represent a ...
... MabVax Therapeutics, Inc., a privately held clinical stage ... antibody based therapies to address the unmet medical need ... the Phase 2 portion of the Small Business Innovation ... under the agency,s Streamlined Non-competing Award Procedures (SNAP). The ...
Cached Biology Technology:Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc. 2Veterinarians and Pet Owners Urged to Act Upon Evolving Dangers Posed by CVBDs as New Research Underlines Threats to Animals and Humans 2Veterinarians and Pet Owners Urged to Act Upon Evolving Dangers Posed by CVBDs as New Research Underlines Threats to Animals and Humans 3Veterinarians and Pet Owners Urged to Act Upon Evolving Dangers Posed by CVBDs as New Research Underlines Threats to Animals and Humans 4MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 2MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 3
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... today announced that members of the executive management team will ... 43rd Annual Technology, Media and Telecom Conference Date: May ... in Boston, MA Cowen ... 2015 Time: 2:45pm ET Location: The New York Palace Hotel, ...
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... shipping to pre-order customers the first week of May, ... the month of May. Gino ... significant milestone for the company as Wocket® enters the ...
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... Charitable Trust has awarded a $2 million grant to ... Illinois at Urbana-Champaign. Under the leadership of Principal Investigator ... the grant will be disbursed over two years to ... theme devoted to the new scientific subdiscipline of synthetic ...
... carbon dioxide (CO2) emitted by human activities. Since the ... the man-made CO2. Billions of planktonic organisms, too tiny ... valuable service possible: When carbon dioxide from the atmosphere ... carbon and other organic components during photosynthesis. Jellyfish and ...
... at the University of Alberta have pinpointed a genetic marker ... to date in Caucasians., Researchers have identified many genetic markers ... which accounts for 80 per cent of all cases. Sambasivarao ... and a researcher at the Cross Cancer Institute, worked with ...
Cached Biology News:Roy J. Carver Charitable Trust funds new research focus at Institute for Genomic Biology 2Fast-sinking jellyfish could boost the oceans' uptake of carbon dioxide 2Fast-sinking jellyfish could boost the oceans' uptake of carbon dioxide 3U of A medical researchers ID genetic marker for sporadic breast cancer 2
... The Mini-PROTEAN 3 Dodeca cell with multi-casting ... of up to 12 mini format handcast (8.3 ... cm) gels. The cell requires 3.4-4.4 L of ... cooling coil that attaches to an external refrigerated ...
... sealing material is suitable for PCR ... down heated lid), especially 384-well formats ... for sample retrieval. Multiple seals can ... Ideal for compound management and high ...
... Western Blot Strong Antibody Stripping Solution is ... blots that have been developed with chemiluminescence ... is not recommended for stripping colorimetric substrates ... not possible to effectively remove substrates that ...
... gun low-pressure system, 100-120 V, is used ... cells. The system includes the Helios gene ... prep station, syringe kit, tubing cutter, Helios ... instructions. The dimensions of the gene gun ...
Biology Products: